Table 3.
Weighted mean prices of typical chemotherapy doses in USD, standard pediatric patient (29 kg, BSA 1 m2).
Chemotherapy |
WB income classification |
WHO region |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
Name (Dosage form) | Dose range | HIC | UMIC | LLMIC | AFRO | AMR | EMRO | EURO | SEARO | WPRO |
Asparaginase (IV) | 6000 IU/m2 | 31.10 | 21.50 | 21.03 | 47.56 | 43.13 | 21.05 | 36.17 | 15.78 | 18.78 |
Bleomycin (IV) | 5 mg/m2–15 mg/m2 | 5.02–15.06 | 3.83–11.48 | 5.52–16.55 | 7.46–22.37 | 9.74–29.22 | 6.33–18.99 | 2.66–7.98 | 5.83–17.48 | 10.44–31.31 |
Carboplatin (IV) | 100 mg/m2–600 mg/m2 | 19.24–115.44 | 9.02–54.12 | 8.63–51.78 | 5.97–35.82 | 7.27–43.62 | 9.74–58.44 | 20.44–122.64 | 9.33–55.98 | 19.91–119.46 |
Cisplatin (IV) | 20 mg/m2–100 mg/m2 | 7.67–38.35 | 1.89–9.46 | 1.38–6.90 | 3.04–15.19 | 4.00–20.01 | 0.32–1.61 | 3.88–19.38 | 1.29–6.44 | 6.22–31.10 |
Cyclophosphamide (IV) | 250 mg/m2–2100 mg/m2 | 40.88–343.35 | 2.00–16.80 | 2.93–24.57 | 2.48–20.79 | 99.28–833.91 | 1.45–12.18 | 6.25–52.50 | 3.30–27.72 | 2.70–22.68 |
Cytarabine (IV) | 50 mg/m2- 3000 mg/m2 | 1.35–81.00 | 1.45–87.00 | 0.65–39.00 | 1.00–59.70 | 0.55–32.70 | 0.79–47.10 | 1.32–79.20 | 1.06–63.30 | 2.03–121.80 |
Dacarbazine (IV) | 375 mg/m2–800 mg/m2 | 28.76–61.36 | 24.64–52.56 | 19.91–42.48 | 48.30–103.04 | 22.95–48.96 | 15.83–33.76 | 19.43–41.44 | 38.59–82.32 | 49.09–104.72 |
Dactinomycin (IV) | 45 mcg/kg | 583.99 | 82.22 | 64.47 | 148.25 | 1632.56 | 247.56 | 120.71 | 13.57 | 77.00 |
Daunorubicin (IV) | 20 mg/m2–60 mg/m2 | 37.02–111.07 | 4.17–12.52 | 7.72–23.15 | 14.36–43.09 | 69.97–209.91 | 8.51–25.52 | 18.56–55.67 | 7.47–22.40 | 7.89–23.66 |
Doxorubicin (IV) | 20 mg/m2–75 mg/m2 | 12.12–45.47 | 6.84–25.65 | 8.61–32.28 | 5.24–19.67 | 6.22–23.34 | 6.15–23.07 | 11.37–42.65 | 11.10–41.63 | 14.25–53.45 |
Etoposide (IV) | 75 mg/m2–200 mg/m2 | 9.45–25.20 | 2.18–5.80 | 2.63–7.00 | 6.83–18.20 | 5.27–14.04 | 4.06–10.82 | 7.54–20.10 | 3.14–8.38 | 5.67–15.12 |
Idarubicin (IV) | 5 mg/m2–12 mg/m2 | 79.49–190.78 | 126.57–303.76 | 82.31–197.53 | 51.55–123.72 | 52.33–125.58 | 61.89–148.54 | 74.47–178.73 | 102.34–245.62 | 139.92–335.80 |
Ifosfamide (IV) | 1800 mg/m2–5000 mg/m2 | 59.58–165.50 | 32.58–90.50 | 60.48–168.00 | 72.54–201.50 | 56.16–156.00 | 46.98–130.50 | 57.60–160.00 | 69.12–192.00 | 35.82–99.50 |
Mercaptopurine (tab) | 50 mg/m2–75 mg/m2 | 1.55–2.33 | 0.49–0.74 | 0.22–0.33 | 2.77–4.16 | 1.30–1.94 | 0.59–0.88 | 1.96–2.93 | 0.20–0.29 | 1.04–1.55 |
Methotrexate (IV) | 100 mg/m2–12000 mg/m2 | 8.64–1036.80 | 2.89–346.80 | 2.80–336.00 | 3.13–375.60 | 5.39–646.80 | 3.23–387.60 | 9.17–1100.40 | 2.64–316.80 | 6.36–763.20 |
Methotrexate (tab) | 20 mg/m2 | 4.69 | 1.16 | 0.41 | 0.78 | 6.17 | 0.75 | 1.00 | 0.44 | 5.95 |
Pegaspargase (IV) | 2500 IU/m2 | 3254.50 | 333.25 | – | – | 4384.75 | 1139.25 | 1166.00 | – | 313.00 |
Procarbazine (IV) | 50 mg/m2–100 mg/m2 | 5.57–11.13 | 3.00–5.99 | 0.51–1.02 | 6.56–13.12 | 56.33–112.66 | 3.54–7.08 | 4.20–8.39 | 0.34–0.68 | 1.03–2.05 |
Rituximab (IV) | 375 mg/m2 | 1737.68 | 867.26 | 650.03 | 756.19 | 2336.44 | 1138.05 | 1064.55 | 624.41 | 1186.76 |
Thiotepa (IV) | 200 mg/m2–300 mg/m2 | 2766.46–4149.69 | 2435.14–3652.71 | – | – | 9055.38–13,583.07 | – | 1914.32–2871.48 | – | 707.28–1060.92 |
Thioguanine (tab) | 30 mg/m2–100 mg/m2 | 5.72–19.05 | 2.40–8.01 | 0.37–1.23 | 4.44–14.79 | 10.06–33.54 | 1.67–5.55 | 4.81–16.03 | 0.54–1.80 | 4.16–13.88 |
Vinblastine (IV) | 6 mg/m2 | 12.48 | 3.12 | 3.98 | 1.20 | 17.12 | 4.55 | 8.22 | 2.95 | 14.35 |
Vincristine (IV) | 1 mg/m2–2 mg/m2 | 8.73–17.46 | 3.00–6.01 | 2.64–5.28 | 3.64–7.27 | 4.93–9.86 | 3.46–6.92 | 6.05–12.10 | 2.64–5.28 | 8.35–16.70 |
USD: United States dollars; WB: World Bank; WHO: World Health Organization; HIC: high income countries; UMIC: upper middle income countries; LLMIC: low and lower middle income countries; AFR: African Region; EMR: Eastern Mediterranean Region: EUR: European Region; AMR: Region of the Americas; SEAR: South-East Asian Region; WPR: Western Pacific Region; IV: intravenous; tab: tablet; IU: international unit; kg: kilogram; g: gram; mg: milligram; m: meter.
Source: This is based on internal analysis by Catherine Habashy, Tatenda Yemeke, Nancy Bolous, Yichen Chen, Sachiko Ozawa, Nickhill Bhakta, and Thomas Alexander using data from the following source: IQVIA MIDAS Quarterly Sales for the period 2012–2019 reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.